Status:
COMPLETED
Use of Venetoclax , AML , Sohag , Egypt
Lead Sponsor:
Sohag University
Conditions:
AML (Acute Myelogenous Leukemia)
Eligibility:
All Genders
18-80 years
Brief Summary
retrospective observational study to evaluate the benefit of adding venetoclax to chemotherapy in the first or second line setting in Sohag governorate.
Detailed Description
Acute Myeloid Leukaemia (AML) is an aggressive and most common hematologic malignancy in adults with a higher incidence in older adults with a median age of diagnosis of 68 years. It accounts for the ...
Eligibility Criteria
Inclusion
- Patients aged between 18 and 80 years.
- Pathological confirmation of AML.
- Use of venetoclax plus chemotherapy as a 1st versus 2nd line treatment.
Exclusion
- age \< 18 years age \> 80 years other types of acute leukemia
- \-
Key Trial Info
Start Date :
March 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2025
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT06993883
Start Date
March 1 2023
End Date
April 30 2025
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sohag Faculty of Medicine
Sohag, Select, Egypt, 82524